Passage Bio, Inc. Form 8-K Summary
Reporting date: July 26, 2023; filed July 31, 2023. The filing reports board changes under Item 5.02. It does not provide financial results or operating-period data.
Business Context and Governance Changes
- Thomas Woiwode, Ph.D. resigned from the Board of Directors and its Compensation Committee effective July 26, 2023.
- The company stated that Dr. Woiwode’s resignation was not due to any disagreement concerning company operations, policies, or practices.
- On July 27, 2023, the Board appointed Dolan Sondhi, Ph.D. as a Class II director to fill the vacancy and appointed her to the Governance Committee.
- Dr. Sondhi is a research professor and gene-therapy specialist at Weill Cornell Medicine, with experience in translational medicine and gene-therapy product manufacturing.
Financial and Other Key Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash runway, or other financial metrics.
Compensation and Equity Award
- Dr. Sondhi will receive cash compensation under the company’s current director compensation policy.
- The Board granted her non-incentive stock options to purchase up to 48,000 shares under the 2020 Equity Incentive Plan.
- The options vest in substantially equal monthly installments over three years, subject to continued service.
- The company will enter into an indemnification agreement with Dr. Sondhi in the same form used for its other directors.
Outlook, Risks, and Unusual Items
No financial guidance, operating outlook, contingencies, or new business risks are disclosed. The principal unusual item is the immediate resignation of a director and the related appointment and equity award.
Investor Verification Points
- Verify the effective date of Dr. Woiwode’s resignation and the July 27 appointment date for Dr. Sondhi.
- Review the company’s director compensation policy and the detailed terms of the 48,000 stock options.
- Assess any governance, committee-composition, or dilution implications from the board transition and equity award.
- Confirm that no financial results or guidance were included in this filing; those items must be obtained from other SEC filings.